ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Salma Health, Inc.5,000 enrolled

Overview

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Depressed Mood

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults (≥18 years) of any gender identity presenting for care with a depressed mood. * Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care. * Able to provide informed consent and comply with all study requirements. Exclusion Criteria: * Any condition deemed by the investigator to preclude safe participation in study assessments.

Locations (2)

Outcomes

Primary Outcomes

Patient Health Questionnaire 9-item (PHQ-9)

The Patient Health Questionnaire (PHQ-9) is a 9-item multipurpose self-report instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Time frame: Pre-treatment, Post-treatment, 2 weeks posttreatment, and Monthly post-treatment for 12 months